PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)
| Market Cap | 89.06M+19.3% |
| Revenue (ttm) | 0 |
| Net Income | -75.22M+7.0% |
| EPS | -1.42+9.6% |
| Shares Out | 53.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,123,324 |
| Open | 1.44 |
| Previous Close | 1.43 |
| Day's Range | 1.44 - 1.73 |
| 52-Week Range | 1.02 - 1.88 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 5.00(+199.40%) |
| Earnings Date | Nov 11, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About PMVP
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PMVP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PMVP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PMVP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PMVP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PMVP Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Development | $19.35M | 40.69% |
| Loss from Operations | $18.88M | 39.70% |
| External | $3.30M | 6.94% |
| Personnel related | $2.99M | 6.29% |
| Stock-based compensation | $1.54M | 3.24% |
| Research | $1.49M | 3.13% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PMVP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PMVP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PMVP
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.80M |
| VXFVanguard Extended Market ETF | $547.36K |
| IWCiShares Micro-Cap ETF | $209.70K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $110.00K |
| PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | $23.24K |
| AVTMAvantis Total Equity Markets ETF 1 | $6.74K |
Estimated from each fund’s disclosed top holdings × AUM
PMVP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PMVP’s recent data — informational, not investment advice